At the news
? BEARISHIMPACT 7/10 CLUSTER filed Mar 26, 2026 at 20:00 ET
Two corporate insiders at AnaptysBio sold shares worth $731K within a 7-day window, including CEO Daniel Faga and Director John Schmid, shortly after the company announced a securities purchase agreement related to a spin-off of its subsidiary First Tracks Biotherapeutics. The timing suggests potential awareness of material non-public developments.
- CEO Daniel Faga and Director John Schmid sold a combined $731K in shares over 7 days
- Sales occurred between March 27 and March 30, 2026, immediately following an 8-K filing disclosing a material agreement for a spin-off and private placement
- Total insider selling represents approximately 0.046% of AnaptysBio's $1.6B market cap
- The 8-K (filed March 27) disclosed a securities purchase agreement for First Tracks Biotherapeutics, a wholly-owned subsidiary, to be spun off to AnaptysBio shareholders
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access